Sowell Financial Services LLC Sells 21,713 Shares of Boston Scientific Corporation $BSX

Key Points

• Sowell Financial Services cut its Boston Scientific stake by 78.8%, selling 21,713 shares and leaving 5,833 shares valued at about $556,000.
• CEO Michael F. Mahoney sold 160,901 shares for roughly $15.04 million, reducing his holding by 10.23%.
• Analysts maintain a consensus "Moderate Buy" with a $104.05 price target amid several price-target cuts, while Boston Scientific reported an EPS beat and set FY‑2026 guidance of 3.430–3.490 EPS.

Sowell Financial Services LLC lessened its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 78.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,833 shares of the medical equipment provider's stock after selling 21,713 shares during the quarter. Sowell Financial Services LLC's holdings in Boston Scientific were worth $556,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in BSX. FWL Investment Management LLC bought a new stake in Boston Scientific during the second quarter worth $26,000. Steph & Co. bought a new stake in Boston Scientific in the third quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp raised its stake in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 170 shares during the period. Financial Consulate Inc. bought a new stake in Boston Scientific in the third quarter valued at approximately $25,000. Finally, United Community Bank raised its stake in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 147 shares during the period. Institutional investors own 89.07% of the company's stock.

Analysts Set New Price Targets

BSX has been the topic of several research analyst reports. Argus upgraded Boston Scientific to a "strong-buy" rating in a research note on Thursday, February 26th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a research report on Monday, February 2nd. Wells Fargo & Company dropped their price objective on shares of Boston Scientific from $125.00 to $94.00 and set an "overweight" rating on the stock in a research report on Thursday, February 5th. Mizuho dropped their price objective on shares of Boston Scientific from $140.00 to $115.00 and set an "outperform" rating on the stock in a research report on Thursday, February 5th. Finally, UBS Group dropped their price objective on shares of Boston Scientific from $120.00 to $105.00 and set a "buy" rating on the stock in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $104.05.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $61.31 on Friday. The firm has a 50 day moving average of $72.11 and a 200-day moving average of $88.38. The stock has a market capitalization of $91.12 billion, a PE ratio of 31.60, a PEG ratio of 0.97 and a beta of 0.78. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 12 month low of $60.59 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion during the quarter, compared to analysts' expectations of $5.29 billion. During the same period in the previous year, the company earned $0.70 EPS. The business's revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Recent company fundamentals remain a support: Boston Scientific reported a recent quarter with revenue growth and an EPS beat, and management set FY‑2026 guidance — facts that underpin longer‑term earnings expectations.
• Neutral Sentiment: Startups and competitors continue to raise capital in the thrombectomy and endovascular spaces, keeping competition and M&A dynamics active (could pressure or spur strategic moves). E2 raises $80M to market thrombectomy platform
• Neutral Sentiment: Industry commentary and longer‑term analyst pieces debate valuation after a sharp pullback; these pieces can encourage opportunistic buyers but also reflect lingering investor caution. Is It Time To Revisit Boston Scientific (BSX)...
• Negative Sentiment: Multiple law firms have filed or are soliciting clients in a securities class‑action covering the July 23, 2025–Feb 3, 2026 period and are reminding investors of a May 4, 2026 lead‑plaintiff deadline — a sustained wave of litigation notices increases legal uncertainty and potential liability. Representative filing/notice: ROSEN law firm notice re BSX class action
• Negative Sentiment: Regulatory/transaction scrutiny: an investor alert has been issued about the proposed Penumbra acquisition (questions over price/process could complicate the deal and create headline risk). Penumbra investor alert re Boston Scientific deal
• Negative Sentiment: Sell‑side and research downgrades/estimate trims: Citigroup and other firms have lowered expectations or price targets, and at least one regional analyst trimmed FY‑2026 EPS modestly — pressure on near‑term sentiment and target prices. Citigroup lowers expectations for BSX

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company's stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.34% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.